

# Trimurthi Drugs & Pharmaceuticals Ltd.

35

## TRIMURTHY DRUGS & PHARMACEUTICALS LIMITED UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED JUNE, 2012

(Rs. In Lakhs)

Particulars	3 Months ended 30-06-2012	Preceeding 3 months ended 31- 03-2012	Corresponding 3 months ended 30- 06-2011	Year to date figures for 12 months ended 31-03-2012	Previous year ended 31-03-2011
	Unaudited	Unaudited	Unaudited	Audited	Audited
1. Net Sales / Income from Operations	155.82	214.37	319.55	1109.71	1651.92
2. Other Income	15.97	15.44	15.14	73.89	62.09
3. Total Income	171.79	229.81	334.69	1183.60	1714.01
4. Expenditure					
a. (Increase)/Decrease in stock in trade and work in Progress	(9.94)	5.75	6.29	39.69	(19.96)
b. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil
c. Purchase of Traded Goods	148.38	196.69	293.77	997.46	1568.80
d. Employees Cost	5.48	8.09	5.53	27.41	28.82
e. Rent	1.77	1.95	1.68	7.08	7.02
f. Depreciation	6.58	6.05	Nil	26.21	26.13
g. Other Expenditure	5.30	7.39	8.18	24.39	32.35
Total	157.55	225.92	315.45	1122.24	1643.16
5. Interest	0.00	0.16	0.00	0.85	1.33
6. Exceptional items	Nil	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	14.24	3.73	19.24	60.51	69.52
8. Tax Expense (Including Deferred and Finge Benefit tax)	3.84	(1.32)	0.00	14.10	22.31
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	10.40	5.05	19.24	46.41	47.21
10. Extraordinary Items	Nil	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	10.40	5.05	19.24	46.41	47.21
12. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.00	675.00	675.00	675.00	675.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	134.02	111.15	87.47	111.15	111.15
14. Earnings Per Share (EPS)					
a. Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.15	0.07	0.29	0.69	0.70
15. Public Share Holding					
- Number of Shares	2016200	2016200	20162000	2016200	2016200
- Percentage of shareholding	29.87%	29.87%	29.87%	29.87%	29.87%
16. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
a. Non encumbered					
- No of Equity Shares	4733800	4733800	47338000	4733800	4733800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	70.13%	70.13%	70.13%	70.13%	70.13%

**TRIMURTHY DRUGS & PHARMACEUTICALS LIMITED**  
UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED JUNE, 2012

Segment Reporting


Particulars	Quarters ended			Year ended	
	30/06/2012	31/03/2012	30/06/2011	31/03/2012	31/03/2011
	Unaudited	Unaudited	Unaudited	Audited	Audited
<b>1. Segment Revenue</b>					
a. Pharma Business	156.10	216.88	320.93	1117.10	1661.83
b. Financial Services	15.69	12.90	13.76	59.65	52.14
c. Investments	0.00	0.00	50.54	6.85	0.05
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>171.79</b>	<b>229.78</b>	<b>385.23</b>	<b>1183.60</b>	<b>1714.02</b>
<b>2. Segment Profits</b>					
a. Pharma Business	0.17	(7.07)	7.13	1.40	25.37
b. Financial Services	14.07	10.79	12.11	52.27	44.08
c. Investment in shares	0.00	0.00	0.00	6.85	0.05
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>14.24</b>	<b>3.72</b>	<b>19.24</b>	<b>60.52</b>	<b>69.50</b>
<b>3. Capital Employed</b>					
a. Pharma Business	257.02	299.55	345.25	268.32	321.06
b. Financial Services	436.86	409.82	383.08	410.17	328.49
c. Investments	50.54	50.54	0.00	50.54	51.89
d. Trading in Shares	0.00	0.00	0.00	Nil	0.00
<b>Total</b>	<b>744.42</b>	<b>759.91</b>	<b>728.33</b>	<b>729.02</b>	<b>701.44</b>

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 21/07/2012.
- The financial results for the quarter ended 30-06-2012 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- The status of investor grievances for the quarter ended 30-06-2012
  - pending at the beginning - Nil
  - received - 1
  - settled - 1
  - pending at the end - Nil

Place: Hyderabad,  
Date : 21/07/2012.

for: TRIMURTHI DRUGS AND PHARMACEUTICALS LIMITED



Arvind Kumar Bhangadia  
Managing Director

# K. Venkateswara Rao & Associates

Chartered Accountants

Flat No. 105, 1st Floor, Pooja Manor, Himayath Nagar, Hyderabad - 500 029.

37

## Annexure V to Clause 41

Review Report to:

The Board of Directors,  
Trimurthi Drugs & Pharmaceuticals Limited  
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of **TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED** for the period ended **30<sup>th</sup> June, 2012**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (Note 1) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS  
FRN : 006374S

PLACE: HYDERABAD  
DATE: 21.07.2012

K.VENKATESWARA RAO  
PROPRIETOR  
M.No. 200/27305

**Note 1.** The Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 and/or Accounting Standards issued by Institute of Chartered Accountants of India.